Quantcast

Latest 5-HT3 antagonist Stories

2014-10-23 08:37:02

LUGANO, Switzerland, October 23, 2014 /PRNewswire/ -- ~ At a dose of 20 mug/kg, Palonosetron, administered as a singledose, is as effective as ondansetron 0.15 mg/kg given three times a day to a maximum dose of 32mg ~ No safety concerns were raised by the study Helsinn Group, the company focused on building quality cancer care, presented data at the International Society of Paediatric Oncology (SIOP) congress establishing that palonosetron, at a dose 20 mug/kg, is a...

2014-10-20 20:25:49

LONDON, Oct. 20, 2014 /PRNewswire/ -- Report DetailsTreatments for nausea and vomiting - explore business trends, R&D, and revenue forecastsWhat's the future of treating nausea and vomiting? For those medicines you get sales predictions, also exploring research and development. Those treatments hold high potential. There you assess results, progress, therapies, and opportunities.Visiongain's new report forecasts those revenues to 2024 at overall world market, submarket, product,...

2014-10-13 08:26:31

-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV -- LUGANO, Switzerland and WOODCLIFF LAKE, N.J., Oct. 13, 2014 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO(®) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is the first approved fixed...

2014-10-07 04:22:07

CAMBRIDGE, England, October 7, 2014 /PRNewswire/ -- Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours...

2014-07-17 04:20:49

LUGANO, Switzerland and TOKYO, July 17, 2014 /PRNewswire/ -- Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the UK and NEPA in the UK and in Ireland from Helsinn Group, strengthening the existing alliance between the companies in therapeutic area of supportive cancer care. Helsinn, the Swiss Group focused on building quality cancer care, and Chugai Pharmaceutical Co., Ltd. today announced that exclusive rights to...

2014-07-10 08:27:07

LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule of netupitant 300 mg + oral palonosetron 0.50 mg (NEPA), which is licensed to Eisai Inc. in the United States, have been published, together with an accompanying editorial, in the July issue of Annals of Oncology....

2014-06-26 08:27:36

WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, June 26, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed-dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV), will be presented at the International Symposium on Supportive Care in Cancer. The Multinational Association of Supportive Care in...

2014-05-28 16:26:44

-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting -- WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, May 28, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI(®) (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly...

2014-01-29 16:29:05

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bgdzzw/tesaros) has announced the addition of the "Tesaro's Rolapitant: Competition for Emend" [http://www.researchandmarkets.com/research/bgdzzw/tesaros ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Tesaro's rolapitant is a NK-1 inhibitor in phase III trials for the prophylaxis of chemotherapy-induced nausea and...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.